Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pegylated interferon: the who, why, and how

6 Dec 2024

Abstract excerpt

Interferon alpha (IFN-α) is a fascinating molecule with many biological properties yet to be fully understood. Among these properties, several have demonstrated usefulness for targeting malignant cells, including hematopoietic cells from patients with myeloproliferative neoplasms. Indeed, IFN-α has been used for decades across all myeloproliferative neoplasms, but only recently a new form, ropegIFN-α2b, was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Eosinophilic Disorders and Syndromes
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39644027
DOI: 10.1182/hematology.2024000577

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pegylated interferon: the who, why, and howPMID 39644027Read ↗

Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?Semantic proximity Read ↗

Long-acting interferon: pioneering disease modification of myeloproliferative neoplasms.Semantic proximity Read ↗

Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses.Semantic proximity Read ↗

Contemporary Use of Interferon Therapy in the Myeloproliferative Neoplasms.Semantic proximity Read ↗

A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera.Semantic proximity Read ↗

Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations.Semantic proximity Read ↗

[Efficacy and safety of peginterferon-α2b for treatment of myeloproliterative neoplasms].Semantic proximity Read ↗

Optimizing IFN Alpha Therapy against Myeloproliferative Neoplasms.Semantic proximity Read ↗

Real-world experience with Ropeginterferon-alpha 2b (Besremi) in Philadelphia-negative myeloproliferative neoplasms.Semantic proximity Read ↗

Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a.Semantic proximity Read ↗

Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.Semantic proximity Read ↗

Emerging treatments for classical myeloproliferative neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.